Low-dose GH supplementation reduces the TLR2 and TNF-α expressions in visceral fat

被引:11
作者
Kubota, Yoshitaka [2 ]
Unoki, Hiroyuki [3 ]
Bujo, Hideaki [1 ]
Rikihisa, Naoaki [2 ]
Udagawa, Akikazu [2 ]
YoshiMoto, Shinya [2 ]
Ichinose, Masaharu [2 ]
Saito, Yasushi [4 ]
机构
[1] Chiba Univ, Grad Sch Med, Dept Genome Res & Clin Applicat, Chiba 2608670, Japan
[2] Chiba Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Chiba 2608670, Japan
[3] Chiba Univ, Grad Sch Med, Dept Appl Translat Res, Chiba 2608670, Japan
[4] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chiba 2608670, Japan
关键词
growth hormone; toll-like receptor 2; adipocyte; visceral fat; insulin-like growth factor-1;
D O I
10.1016/j.bbrc.2008.01.035
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The increased population of TLR2/TNF-alpha co-expressing adipocytes is associated with the development of insulin resistance. We have herein shown the significance of low-dose growth hormone (GH) supplementation for the regulation of TLR2 and TNF-alpha expressions in visceral fat using different kinds of mouse models fed with a high-fat diet. Low-dose GH supplementation reduced the increased population of TLR2/TNF-alpha co-expressing adipocytes in high-fat fed mice. The neutralization of IGF-1 abolished the effect of GH supplementation on the TLR2 expression using GH-overexpressing mice. IGF-1, but not GH, inhibited the FFA-induced TLR2 and TNF-alpha expression in 3T3-L1 cells. Finally, low-dose GH supplementation reduced the TLR2 expression without an obvious change in the visceral fat volume in ob/ob mice. These results indicate that low-dose GH supplementation possibly inhibits the high-fat induced change of the adipocytes to TLR2/TNF-alpha co-expressing cells through the action of 1GF-1. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 18 条
[1]
Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control [J].
Ahn, CW ;
Kim, CS ;
Nam, JH ;
Kim, HJ ;
Nam, JS ;
Park, JS ;
Kang, ES ;
Cha, BS ;
Lim, SK ;
Kim, KR ;
Lee, HC ;
Huh, KB .
CLINICAL ENDOCRINOLOGY, 2006, 64 (04) :444-449
[2]
HUMAN GROWTH-HORMONE AND HUMAN AGING [J].
CORPAS, E ;
HARMAN, SM ;
BLACKMAN, MR .
ENDOCRINE REVIEWS, 1993, 14 (01) :20-39
[3]
Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes:: Evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor γ2 [J].
Dieudonne, MN ;
Pecquery, R ;
Leneveu, MC ;
Giudicelli, Y .
ENDOCRINOLOGY, 2000, 141 (02) :649-656
[4]
Inhibition of death-receptor mediated apoptosis in human adipocytes by the insulin-like growth factor I (IGF-I)/IGF-I receptor autocrine circuit [J].
Fischer-Posovszky, P ;
Tornqvist, H ;
Debatin, KM ;
Wabitsch, M .
ENDOCRINOLOGY, 2004, 145 (04) :1849-1859
[5]
Controversy in clinical endocrinology - Metabolic syndrome: A multiplex cardiovascular risk factor [J].
Grundy, Scott M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02) :399-404
[6]
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment [J].
Heffernan, MA ;
Thorburn, AW ;
Fam, B ;
Summers, R ;
Conway-Campbell, B ;
Waters, MJ ;
Ng, FM .
INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (10) :1442-1449
[7]
Activation of diacylglycerol O-acyltransferase 1 gene results in increased tumor necrosis factor-α gene expression in 3T3-L1 adipocytes [J].
Hirata, Takashi ;
Unoki, Hiroyuki ;
Bujo, Hideaki ;
Ueno, Koichi ;
Saito, Yasushi .
FEBS LETTERS, 2006, 580 (21) :5117-5121
[8]
Fat as an endocrine organ: Relationship to the metabolic syndrome [J].
Hutley, L ;
Prins, JB .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2005, 330 (06) :280-289
[9]
Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice [J].
Ito, M ;
Bujo, H ;
Takahashi, K ;
Arai, T ;
Tanaka, I ;
Saito, Y .
DIABETOLOGIA, 2005, 48 (08) :1614-1620
[10]
Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure [J].
Johannsson, G ;
Marin, P ;
Lonn, L ;
Ottosson, M ;
Stenlof, K ;
Bjorntorp, P ;
Sjostrom, L ;
Bengtsson, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (03) :727-734